Metalloproteinases in Ovarian Cancer.
extracellular matrix
matrix metalloproteinase
mesenchymal
mesothelial cells
ovarian cancer
peritoneum
proteases
proteolysis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Mar 2021
26 Mar 2021
Historique:
received:
17
02
2021
revised:
21
03
2021
accepted:
25
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
21
4
2021
Statut:
epublish
Résumé
Proteases play a crucial role in the progression and metastasis of ovarian cancer. Pericellular protein degradation and fragmentation along with remodeling of the extracellular matrix (ECM) is accomplished by numerous proteases that are present in the ovarian tumor microenvironment. Several proteolytic processes have been linked to cancer progression, particularly those facilitated by the matrix metalloproteinase (MMP) family. These proteases have been linked to enhanced migratory ability, extracellular matrix breakdown, and development of support systems for tumors. Several studies have reported the direct involvement of MMPs with ovarian cancer, as well as their mechanisms of action in the tumor microenvironment. MMPs play a key role in upregulating transcription factors, as well as the breakdown of structural proteins like collagen. Proteolytic mechanisms have been shown to enhance the ability of ovarian cancer cells to migrate and adhere to secondary sites allowing for efficient metastasis. Furthermore, angiogenesis for tumor growth and development of metastatic implants is influenced by upregulation of certain proteases, including MMPs. While proteases are produced normally in vivo, they can be upregulated by cancer-associated mutations, tumor-microenvironment interaction, stress-induced catecholamine production, and age-related pathologies. This review outlines the important role of proteases throughout ovarian cancer progression and metastasis.
Identifiants
pubmed: 33810259
pii: ijms22073403
doi: 10.3390/ijms22073403
pmc: PMC8036623
pii:
doi:
Substances chimiques
Matrix Metalloproteinases
EC 3.4.24.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : UO1CA236797
Pays : United States
Organisme : NIH HHS
ID : RO1CA109545
Pays : United States
Organisme : NIH HHS
ID : F99AG068527
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA236979
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA109545
Pays : United States
Références
Cancer Lett. 2016 Jul 28;377(2):174-82
pubmed: 27131957
Biol Chem. 2014 Oct;395(10):1221-31
pubmed: 25205731
Cell Cycle. 2009 Mar 1;8(5):683-8
pubmed: 19221481
J Cell Biol. 2001 Sep 3;154(5):1069-79
pubmed: 11535623
Am J Pathol. 2004 May;164(5):1511-8
pubmed: 15111296
Oncotarget. 2016 Aug 9;7(32):51553-51568
pubmed: 27303921
Gynecol Oncol. 2001 Feb;80(2):245-53
pubmed: 11161867
Cell Mol Life Sci. 2011 Dec;68(23):3853-68
pubmed: 21744247
J Clin Invest. 2008 Apr;118(4):1367-79
pubmed: 18340378
Oncogene. 2015 Nov 26;34(48):5923-32
pubmed: 25798837
Invasion Metastasis. 1996;16(3):150-9
pubmed: 9186550
Biochem J. 2012 Jul 15;445(2):229-36
pubmed: 22519702
J Cell Sci. 2005 Feb 1;118(Pt 3):485-96
pubmed: 15657080
Cancer Res. 1998 Mar 1;58(5):1048-51
pubmed: 9500469
Clin Cancer Res. 2006 Jan 15;12(2):369-75
pubmed: 16428474
Langmuir. 2014 May 20;30(19):5506-9
pubmed: 24800650
Cancer. 2004 Sep 15;101(6):1364-74
pubmed: 15368324
Clin Cancer Res. 2008 Nov 1;14(21):6839-46
pubmed: 18980978
Cancer Res. 1993 Jan 15;53(2):417-22
pubmed: 8417833
Cancer Res. 2013 Apr 15;73(8):2457-2467
pubmed: 23423981
Oncogene. 2009 Nov 5;28(44):3937-48
pubmed: 19701247
Am J Pathol. 2002 Feb;160(2):537-48
pubmed: 11839574
J Biomed Biotechnol. 2012;2012:564259
pubmed: 23097597
Nat Cell Biol. 2000 Oct;2(10):737-44
pubmed: 11025665
J Biol Chem. 2001 Jul 6;276(27):24833-42
pubmed: 11331272
Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11387-92
pubmed: 20534449
J Natl Cancer Inst. 2015 Feb 20;107(4):
pubmed: 25710962
Cancer Treat Res. 2009;149:319-34
pubmed: 19763443
Cancer. 2002 Aug 15;95(4):808-15
pubmed: 12209725
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Int J Cancer. 2007 Oct 1;121(7):1463-72
pubmed: 17546601
Cardiovasc Res. 2006 Feb 15;69(3):562-73
pubmed: 16405877
Clin Cancer Res. 2001 Aug;7(8):2396-404
pubmed: 11489818
Cell Tissue Res. 2011 Dec;346(3):347-59
pubmed: 22160502
Int J Cancer. 2010 Sep 1;127(5):1081-95
pubmed: 20027628
Cancer Res. 2009 Feb 15;69(4):1517-26
pubmed: 19208838
Gynecol Oncol. 2009 Aug;114(2):265-72
pubmed: 19450871
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3299-304
pubmed: 11006217
Cancer Cell Microenviron. 2014 Nov 13;1(6):e379
pubmed: 26000332
Gynecol Oncol. 2011 Jun 1;121(3):434-43
pubmed: 21421261
Gynecol Oncol. 2001 Aug;82(2):291-8
pubmed: 11531282
J Biol Chem. 1996 Mar 29;271(13):7788-95
pubmed: 8631822
J Biol Chem. 2017 Aug 11;292(32):13111-13121
pubmed: 28655772
Proc Natl Acad Sci U S A. 1987 May;84(9):2776-80
pubmed: 3033662
J Biol Chem. 2001 Oct 5;276(40):37491-500
pubmed: 11448964
Cancer Res. 2002 Mar 15;62(6):1854-61
pubmed: 11912165
Neoplasia. 2018 Jun;20(6):621-631
pubmed: 29754071
PLoS One. 2012;7(7):e41591
pubmed: 22848537
Endocrinology. 1996 Dec;137(12):5597-604
pubmed: 8940389
Matrix Biol. 2015 May-Jul;44-46:94-112
pubmed: 25912949
Clin Cancer Res. 2006 Mar 15;12(6):1876-82
pubmed: 16551873
Nature. 2005 Jul 7;436(7047):123-7
pubmed: 16001073
J Biol Chem. 2004 Mar 5;279(10):9190-8
pubmed: 14676194
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):3884-9
pubmed: 10760260
Brain Behav Immun. 2011 Feb;25(2):250-5
pubmed: 20955777
FEBS Lett. 1997 Mar 24;405(2):157-62
pubmed: 9089282
FASEB J. 2002 Apr;16(6):555-64
pubmed: 11919158
Tumour Biol. 2015 Sep;36(9):6883-9
pubmed: 25851348
N Engl J Med. 1983 Oct 13;309(15):883-7
pubmed: 6310399
Ann Oncol. 2016 Apr;27 Suppl 1:i33-i39
pubmed: 27141068
Blood. 2001 Apr 15;97(8):2323-32
pubmed: 11290594
Cancer Res. 2003 Jun 15;63(12):3403-12
pubmed: 12810677
PLoS One. 2017 Sep 21;12(9):e0184439
pubmed: 28934230
Sci Rep. 2016 Feb 24;6:21903
pubmed: 26906973
J Investig Dermatol Symp Proc. 2009 Aug;14(1):20-4
pubmed: 19675548
Nat Rev Mol Cell Biol. 2007 Mar;8(3):221-33
pubmed: 17318226
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Clin Cancer Res. 2003 Oct 1;9(12):4514-21
pubmed: 14555525
Nat Med. 2006 Aug;12(8):939-44
pubmed: 16862152
J Biol Chem. 2000 Feb 4;275(5):3328-34
pubmed: 10652321
Cancer Res. 2001 Apr 1;61(7):2866-9
pubmed: 11306460
J Biol Chem. 2004 Apr 2;279(14):13564-74
pubmed: 14729679
Cancer Res. 2009 Sep 1;69(17):7121-9
pubmed: 19706774
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
J Neuroimmunol. 2002 Dec;133(1-2):144-50
pubmed: 12446017
Oncotarget. 2017 Aug 10;8(44):76881-76897
pubmed: 29100356
Kidney Int. 2005 Feb;67(2):449-57
pubmed: 15673292
Mol Biol Cell. 2006 Apr;17(4):1922-32
pubmed: 16436508
Oncogene. 2017 Oct 19;36(42):5840-5851
pubmed: 28628116
Cell. 1998 May 1;93(3):411-22
pubmed: 9590175
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10990-5
pubmed: 9724817
J Biol Chem. 2008 Nov 7;283(45):30433-7
pubmed: 18650443
Cancer Sci. 2011 Apr;102(4):815-27
pubmed: 21219539
Curr Pharm Des. 2004;10(1):39-49
pubmed: 14754404
Oncogene. 2014 Jul 10;33(28):3619-33
pubmed: 23934194
J Enzyme Inhib Med Chem. 2016;31(sup1):177-183
pubmed: 27028474
J Clin Oncol. 2000 Mar;18(5):1135-49
pubmed: 10694567
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4052-7
pubmed: 10737763
Oncol Res. 1999;11(10):461-9
pubmed: 10850887
Int J Cancer. 1994 Feb 15;56(4):552-9
pubmed: 8112891
Mol Cancer Res. 2008 Apr;6(4):525-34
pubmed: 18403633
Cancers (Basel). 2018 Jul 10;10(7):
pubmed: 29996539
J Cell Biol. 1998 Aug 24;142(4):1105-19
pubmed: 9722621
Br J Pharmacol. 2019 Jan;176(1):52-66
pubmed: 29488211
J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42
pubmed: 12165638
Cancer Res. 1999 Apr 1;59(7):1635-41
pubmed: 10197640
J Natl Cancer Inst. 2003 Mar 19;95(6):484-6
pubmed: 12644542
Cancer Res. 2007 Mar 1;67(5):2030-9
pubmed: 17332331
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Cancer. 1997 Oct 15;80(8):1457-63
pubmed: 9338470
EMBO J. 2004 Apr 21;23(8):1739-48
pubmed: 15057284
J Biol Chem. 2009 Jul 24;284(30):19791-9
pubmed: 19458085
Gynecol Oncol. 1996 Jul;62(1):89-99
pubmed: 8690299
Endocrine. 1998 Jun;8(3):309-15
pubmed: 9741836
Cancer Lett. 2014 Nov 1;354(1):164-71
pubmed: 25135221
Ann N Y Acad Sci. 2002 Nov;973:31-43
pubmed: 12485830
Fertil Steril. 2000 Sep;74(3):429-38
pubmed: 10973633
Nat Rev Cancer. 2004 Jan;4(1):71-8
pubmed: 14708027
J Biol Chem. 2007 Feb 16;282(7):4924-4931
pubmed: 17158885
J Clin Invest. 2012 Oct;122(10):3603-17
pubmed: 22945634
Breast Cancer Res Treat. 2003 Jul;80(1):63-70
pubmed: 12889599
Braz J Med Biol Res. 2017 May 18;50(6):e6104
pubmed: 28538838
Cancer Res. 2006 Nov 1;66(21):10357-64
pubmed: 17079456
BMC Cancer. 2010 Apr 13;10:139
pubmed: 20388222
Cancer Res. 2002 Jan 15;62(2):580-8
pubmed: 11809713
Am J Pathol. 2010 Sep;177(3):1053-64
pubmed: 20651229
Reproduction. 2015 Aug;150(2):R55-64
pubmed: 25918438
Br J Cancer. 2004 Mar 22;90(6):1265-73
pubmed: 15026811
Blood. 2010 Jan 28;115(4):846-9
pubmed: 19965686
N Engl J Med. 1997 Nov 13;337(20):1419-28
pubmed: 9358139
J Cell Sci. 2008 Nov 15;121(Pt 22):3747-56
pubmed: 18940913
Endocrine. 2001 Jul;15(2):187-92
pubmed: 11720244
Br J Cancer. 2007 Aug 6;97(3):358-67
pubmed: 17609667
J Cell Biol. 1997 Dec 29;139(7):1861-72
pubmed: 9412478